Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31

Journal of Crohn's and Colitis

Volumn 6, Issue 3, 2012, Pages 358-361

  Steenholdt, Casper ^a   Al Khalaf, Magid ^a   Ainsworth, Mark A ^a   Brynskov, Jørn ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anti infliximab antibody; Inflammatory bowel disease; Infliximab; Pregnancy; TNF; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB;

ABDOMINAL PAIN; ADULT; ARTICLE; CASE REPORT; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GESTATIONAL AGE; HEMATOCHEZIA; HUMAN; LIMIT OF DETECTION; MAINTENANCE THERAPY; PLACENTAL TRANSFER; PREGNANCY; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS; VACCINATION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; FEMALE; HUMANS; INFANT; MALE; MATERNAL-FETAL EXCHANGE; PREGNANCY;

EID: 84858079784     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.10.002     Document Type: Article

References (23)

1. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
2. Jarnerot G., Hertervig E., Friis-Liby I., Blomquist L., Karlen P., Granno C., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128:1805-1811.
3. Gisbert J.P. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 2010, 16:881-895.
4. VAN DER Woude C.J., Kolacek S., Dotan I., Oresland T., Vermeire S., Munkholm P., et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2010, 4:493-510.
5. Zelinkova Z., de H.C., de R.L., Pierik M.J., Kuipers E.J., Peppelenbosch M.P., et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011, 33:1053-1058.
6. Vasiliauskas E.A., Church J.A., Silverman N., Barry M., Targan S.R., Dubinsky M.C. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006, 4:1255-1258.
7. Mahadevan U., Terdiman J., Church J., Vasiliauskas E., Gitis A. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterology 2007, 132(Suppl 2):A144.
8. Steenholdt C., Bendtzen K., Brynskov J., Thomsen O.O., Ainsworth M.A. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011, 46:310-318.
9. Bendtzen K., Geborek P., Svenson M., Larsson L., Kapetanovic M.C., Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006, 54:3782-3789.
10. Svenson M., Geborek P., Saxne T., Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007, 46:1828-1834.
11. Radstake T.R., Svenson M., Eijsbouts A.M., van den Hoogen F.H., Enevold C., van Riel P.L., et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1739-1745.
12. Ainsworth M.A., Bendtzen K., Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008, 103:944-948.
13. Bendtzen K., Ainsworth M., Steenholdt C., Thomsen O.O., Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009, 44:774-781.
14. Beaulieu D.B., Kane S. Inflammatory bowel disease in pregnancy. World J Gastroenterol 2011, 17:2696-2701.
15. Moscandrew M., Kane S. Inflammatory bowel diseases and management considerations: fertility and pregnancy. Curr Gastroenterol Rep 2009, 11:395-399.
16. El M.M., El-Hachem S., Harrison J.R., Binion D.G. Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review. Curr Drug Targets 2010, 11:234-241.
17. Stengel J.Z., Arnold H.L. Is infliximab safe to use while breastfeeding?. World J Gastroenterol 2008, 14:3085-3087.
18. Kane S., Ford J., Cohen R., Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 2009, 43:613-616.
19. Kane S.V., Acquah L.A. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009, 104:228-233.
20. Pentsuk N., van der Laan J.W. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 2009, 86:328-344.
21. Sarvas H., Seppala I., Kurikka S., Siegberg R., Makela O. Half-life of the maternal IgG1 allotype in infants. J Clin Immunol 1993, 13:145-151.
22. Ternant D., Aubourg A., Magdelaine-Beuzelin C., Degenne D., Watier H., Picon L., et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008, 30:523-529.
23. Cheent K., Nolan J., Shariq S., Kiho L., Pal A., Arnold J. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010, 4:603-605.